IN2014KN01304A - Improved synergistic anti diabetic compositions - Google Patents
Improved synergistic anti diabetic compositionsInfo
- Publication number
- IN2014KN01304A IN2014KN01304A IN1304/KOLNP/2014A IN1304KON2014A IN2014KN01304A IN 2014KN01304 A IN2014KN01304 A IN 2014KN01304A IN 1304KON2014 A IN1304KON2014 A IN 1304KON2014A IN 2014KN01304 A IN2014KN01304 A IN 2014KN01304A
- Authority
- IN
- India
- Prior art keywords
- compositions
- metabolites
- concerned
- derivatives
- improved synergistic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000002195 synergetic effect Effects 0.000 title abstract 3
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 229940100389 Sulfonylurea Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 229940124530 sulfonamide Drugs 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 229920001202 Inulin Polymers 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 1
- 229940029339 inulin Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000036186 satiety Effects 0.000 abstract 1
- 235000019627 satiety Nutrition 0.000 abstract 1
- -1 sulfonamide compounds Chemical class 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011904887A AU2011904887A0 (en) | 2011-11-23 | Improved synergistic anti-diabetic compositions | |
| AU2012902723A AU2012902723A0 (en) | 2012-06-27 | Improved synergistic anti-diabetic compositions -II | |
| PCT/AU2012/001442 WO2013075172A1 (en) | 2011-11-23 | 2012-11-23 | Improved synergistic anti-diabetic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN01304A true IN2014KN01304A (en) | 2015-10-16 |
Family
ID=48468910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1304/KOLNP/2014A IN2014KN01304A (en) | 2011-11-23 | 2014-06-19 | Improved synergistic anti diabetic compositions |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9737559B2 (enExample) |
| EP (1) | EP2782586A4 (enExample) |
| JP (2) | JP2014533702A (enExample) |
| KR (1) | KR102104384B1 (enExample) |
| CN (1) | CN104244958B (enExample) |
| AU (1) | AU2012343332B2 (enExample) |
| BR (1) | BR112014012401A2 (enExample) |
| CA (1) | CA2861661C (enExample) |
| IN (1) | IN2014KN01304A (enExample) |
| RU (1) | RU2642633C2 (enExample) |
| WO (1) | WO2013075172A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109498611B (zh) * | 2019-01-15 | 2020-09-01 | 张惊宇 | 一种治疗糖尿病周围神经痛的药物及其用途 |
| RU2741079C1 (ru) * | 2020-04-06 | 2021-01-22 | Общество С Ограниченной Ответственностью "Технологии Дкв" | Пищевая добавка «пребио дкв» |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082842A (en) * | 1975-02-21 | 1978-04-04 | Armando Nahle | Medicant composition for the treatment of diabetes |
| US5859037A (en) | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
| EP1310173B2 (en) * | 1997-06-23 | 2014-12-31 | Société des Produits Nestlé S.A. | Composition for providing nutrition to diabetics |
| US20030130205A1 (en) * | 2000-04-12 | 2003-07-10 | Christian Samuel T. | Novel pharmaceutical anti-infective agents containing carbohydrate moieties and methods of their preparation and use |
| US6689385B2 (en) * | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
| WO2004070009A2 (en) * | 2003-01-31 | 2004-08-19 | Targesome Inc. | Targeted multivalent macromolecules |
| US20070004623A1 (en) | 2003-10-27 | 2007-01-04 | Innodia Inc. | Use of hydroxylated amino acids for treating diabetes |
| JP2006052191A (ja) * | 2004-08-16 | 2006-02-23 | Taiyo Kagaku Co Ltd | 糖尿病予防、改善、または治療用組成物 |
| CN1861173A (zh) | 2005-05-13 | 2006-11-15 | 王锦 | 糖尿病人营养治疗药品膳食纤维素粉产品 |
| EP1893041A4 (en) * | 2005-06-17 | 2009-05-13 | Henry H Ottens Mfg Company Inc | FIBER-REINFORCED CEREALS, CEREAL BARS AND FOODS AND METHODS OF MAKING |
| EP1832179B1 (en) * | 2005-12-20 | 2018-11-07 | N.V. Nutricia | Carbohydrate composition and flat glucose response |
| EP2146680B1 (en) * | 2007-05-10 | 2011-10-19 | L'Oréal | Cosmetic composition comprising an inulin derivative in the form of an emulsion expanded in volume |
| US20090214511A1 (en) * | 2008-02-21 | 2009-08-27 | Trung Hong Tran | Digestible compositions of inulin for managing blood glucose levels |
| GB0907019D0 (en) * | 2009-04-24 | 2009-06-03 | Oxford Nutrascience Ltd | Pharmaceutical,therapeutic or nutritional delivery systems for functional ingredients |
| KR20120015335A (ko) * | 2009-05-01 | 2012-02-21 | 마이크로파마 리미티드 | 퇴행성 질환의 예방 및 치료를 위한 박테리아 조성물 |
| AU2011257964B2 (en) * | 2010-05-24 | 2014-10-30 | Ozstar Therapeutics Pty Ltd | Anti-diabetic compositions and methods |
-
2012
- 2012-11-23 JP JP2014542643A patent/JP2014533702A/ja active Pending
- 2012-11-23 WO PCT/AU2012/001442 patent/WO2013075172A1/en not_active Ceased
- 2012-11-23 US US14/359,759 patent/US9737559B2/en active Active
- 2012-11-23 KR KR1020147017070A patent/KR102104384B1/ko active Active
- 2012-11-23 CN CN201280067463.9A patent/CN104244958B/zh active Active
- 2012-11-23 EP EP12851708.3A patent/EP2782586A4/en not_active Ceased
- 2012-11-23 AU AU2012343332A patent/AU2012343332B2/en active Active
- 2012-11-23 CA CA2861661A patent/CA2861661C/en active Active
- 2012-11-23 BR BR112014012401A patent/BR112014012401A2/pt not_active Application Discontinuation
- 2012-11-23 RU RU2014125249A patent/RU2642633C2/ru active
-
2014
- 2014-06-19 IN IN1304/KOLNP/2014A patent/IN2014KN01304A/en unknown
-
2017
- 2017-07-07 JP JP2017133685A patent/JP6609287B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014125249A (ru) | 2015-12-27 |
| AU2012343332A1 (en) | 2014-07-17 |
| AU2012343332B2 (en) | 2017-03-16 |
| JP2014533702A (ja) | 2014-12-15 |
| CA2861661C (en) | 2021-03-16 |
| JP2017226672A (ja) | 2017-12-28 |
| KR20150002575A (ko) | 2015-01-07 |
| RU2642633C2 (ru) | 2018-01-25 |
| EP2782586A1 (en) | 2014-10-01 |
| CN104244958B (zh) | 2017-11-17 |
| WO2013075172A1 (en) | 2013-05-30 |
| JP6609287B2 (ja) | 2019-11-20 |
| US20140303118A1 (en) | 2014-10-09 |
| CN104244958A (zh) | 2014-12-24 |
| KR102104384B1 (ko) | 2020-04-27 |
| US9737559B2 (en) | 2017-08-22 |
| CA2861661A1 (en) | 2013-05-30 |
| BR112014012401A2 (pt) | 2017-06-13 |
| EP2782586A4 (en) | 2015-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013500808A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| BR112015003109A2 (pt) | Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2. | |
| PH12013500472A1 (en) | Piperidinyl-substituted lactams as gpr119 modulators | |
| WO2008013799A3 (en) | Treatment and prevention of cardiovascular disease using mast cell stabilizers | |
| MX339614B (es) | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. | |
| WO2011127304A3 (en) | Methods of treating an overweight subject | |
| MA33043B1 (fr) | Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie | |
| EA200701704A1 (ru) | Аналоги и гибридные полипептиды gip с избираемыми свойствами | |
| WO2013186240A3 (en) | Exendin-4 peptide analogues | |
| WO2012054526A8 (en) | Chemosensory receptor ligand-based therapies | |
| WO2012051567A3 (en) | Obesity-related genes and their proteins and uses thereof | |
| WO2011056447A3 (en) | Methods and kits for preventing hypoglycemia | |
| NZ603614A (en) | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator | |
| PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| TN2010000566A1 (en) | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs | |
| WO2012054527A3 (en) | Chemosensory receptor ligand-based therapies | |
| CY1116808T1 (el) | Συνθεση που περιλαμβανει σκονη μεμβρανης κελυφους αυγου για χρηση στην θεραπεια του διαβητη mellitus | |
| IN2014KN01304A (en) | Improved synergistic anti diabetic compositions | |
| WO2012054530A3 (en) | Chemosensory receptor ligand-based therapies | |
| EA201391063A1 (ru) | Аполипопротеин a-iv в качестве антидиабетического пептида | |
| MY156174A (en) | 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity | |
| NZ599171A (en) | Sulfonamides for the prevention of diabetes | |
| EP2575826A4 (en) | ANTIDIBLE COMPOSITIONS AND METHODS | |
| WO2011111066A3 (en) | Composition and uses thereof |